Metformin modified chitosan as a multi-functional adjuvant to enhance cisplatin-based tumor chemotherapy efficacy.
Int J Biol Macromol
; 224: 797-809, 2023 Jan 01.
Article
en En
| MEDLINE
| ID: mdl-36283555
ABSTRACT
Recently, it was newly revealed that the DNA damage induced by cisplatinum (Cis-Pt) mediated chemotherapy was significantly impaired by the highly expressed programmed death ligand-1 (PD-L1) in tumor cells. Besides, the efficacy of Cis-Pt was also limited due to its severe side effects, especially enhanced drug efflux induced by multidrug resistance protein 1 (MDR-1) and increased tumor metastasis. Up to now, few drugs or carbohydrates could simultaneously solve these defects of Cis-Pt mediated chemotherapy. Here, we newly found that metformin-modified chitosan (Ch-Met) possessed ideal selective mitochondria accumulation capacity, leading to the further disrupted mitochondrial function, which then effectively inhibited the upregulated PD-L1 expression to inhibit DNA damage repair in tumor cells, as well as impaired drug efflux and lowered tumor metastasis. Therefore, it was demonstrated that Ch-Met could sensitize the chemotherapy efficacy of Cis-Pt.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Quitosano
/
Metformina
/
Neoplasias
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Int J Biol Macromol
Año:
2023
Tipo del documento:
Article
País de afiliación:
China